Table 1B. Study subjects: Multiple sclerosis patients.

Age (years)	Gender	Durationa	MSb	Treatmentc
18	Female	4 mos	RR	Prednisone
49	Male	3 mos	RR	None
52	Female	11 years	SP	Interferon β-1a
63	Female	4 years	RR	Fingolimod
47	Female	7 years	RR	Glatiramer acetate
60	Male	21 years	RR	Interferon β-1a
70	Female	40 years	RR	Interferon β-1a
23	Male	5 mos	RR	Prednisone
55	Female	13 years	RR	Glatiramer acetate
69	Female	17 years	RR	Glatiramer acetate
47	Female	2 years	RR	Interferon β-1a
61	Male	14 years	RR	Fingolimod
84	Male	20 years	RR	Interferon β-1a
65	Female	32 years	SP	None
56	Female	3 years	RR	Glatiramer acetate
26	Female	11 mos	RR	Interferon β-1a
61	Female	16 years	PR	Interferon β-1a

Abbreviations: mos, months; PP, primary progressive; PR, progressive relapsing; RR, relapsing remitting; SP, secondary progressive.

^aDuration: time since diagnosis.

^bMS: clinical subtype.

^cTreatment at the time of donating blood sample.